Mononuclear Cell Composition for Mesenchymal Stem Cell Adipogenesis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current fat grafting techniques using mesenchymal stem cells face challenges in achieving consistent clinical results due to issues like partial necrosis and graft volume loss, necessitating improved fat and vascular regeneration capabilities.

Innovation Solution

A composition containing in vitro amplified and cultured mononuclear cell fractions, such as those derived from bone marrow, umbilical cord blood, or peripheral blood, is co-cultured with mesenchymal stem cells to enhance their ability to differentiate into adipocytes, using factors like stem cell growth factors and interleukins in serum-free media.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If adipose tissue is used for fat grafting, then autologous filler availability and natural feel are improved, but graft volume loss due to ischemia occurs

Engineering Contradiction:

Improveautologous filler availabilityVSAvoidgraft volume loss

Core Design Contradiction:

Adaptability or versatilityVSLoss of substance

Solution Approach 1:

The patent applies preliminary action by pre-culturing mesenchymal stem cells with mononuclear cell fractions before grafting to enhance their adipogenic differentiation capacity and angiogenic potential in advance, thereby improving graft survival and reducing volume loss

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses mononuclear cell fractions as an intermediary substance that mediates between the graft and host environment, promoting angiogenesis and reducing inflammation to improve graft integration and reduce volume loss

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If mesenchymal stem cells are used to enhance fat grafting, then fat and vascular regeneration capabilities are improved, but consistent clinical results are difficult to achieve

Engineering Contradiction:

Improvefat regeneration capabilityVSAvoidclinical result consistency

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies parameter changes by modifying the cellular composition parameters through co-culture with mononuclear cell fractions, which enhances adipogenic differentiation capacity and angiogenic potential, leading to more consistent and reliable clinical outcomes

Inventive Principle:

Principle #35Parameter changes

3Productivity

If in vitro amplified mononuclear cell fraction is co-cultured with mesenchymal stem cells, then adipogenic differentiation capacity is improved, but culture time and process complexity increase

Engineering Contradiction:

Improveadipogenic differentiation capacityVSAvoidculture process complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent applies self-service by utilizing the natural interactions between mononuclear cell fractions and mesenchymal stem cells in co-culture, where the mononuclear cells provide growth factors and signals that automatically enhance adipogenic differentiation without requiring additional external interventions

Inventive Principle:

Principle #25Self-service

Data Source

PatentEP4636077A1Composition for amplifying ability of mesenchymal stem cells to differentiate into adipocytes

Publication Date: 2025.10.22 JUNTENDO EDUCATIONAL FOUNDATION

Figure 1
Figure 2A~2B
Figure 3

AI summary

The present invention relates to a composition and a method for amplifying ability of a mesenchymal stem cell to differentiate into an adipocyte. The composition of the present invention contains in vitro amplified and cultured mononuclear cell fraction, and is co-cultured with a mesenchymal stem cell. The method of the present invention is a method for amplifying ability of a mesenchymal stem cell to differentiate into an adipocyte comprising co-culturing in vitro amplified and cultured mononuclear cell fraction with a mesenchymal stem cell.